ALK and non-small cell lung carcinoma: In conclusion, our study indicated that for patients with ALK-positive NSCLC, a more cost-effective strategy would be to reserve brigatinib followed by lorlatinib until subsequent lines of therapy instead of the use of first-line brigatinib followed by lorlatinib.